Zobrazeno 1 - 10
of 278
pro vyhledávání: '"Hallvard Holdaas"'
Autor:
Obbo W. Bredewold, MD, Joe Chan, My Svensson, Annette Bruchfeld, Johan W. de Fijter, Hans Furuland, Josep M. Grinyo, Anders Hartmann, Hallvard Holdaas, Olof Hellberg, Alan Jardine, Lars Mjörnstedt, Karin Skov, Knut T. Smerud, Inga Soveri, Søren S. Sørensen, Anton-Jan van Zonneveld, Bengt Fellström
Publikováno v:
Kidney Medicine, Vol 5, Iss 1, Pp 100574- (2023)
Rationale & Objective: In kidney transplant recipients (KTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors compared with calcineurin inhibitor (CNI)–based regimens. Our obje
Externí odkaz:
https://doaj.org/article/c79dbfeee8274a49bb87981258c2c2b4
Autor:
Hege Kampen Pihlstrøm, Thor Ueland, Annika E Michelsen, Pål Aukrust, Franscesca Gatti, Clara Hammarström, Monika Kasprzycka, Junbai Wang, Guttorm Haraldsen, Geir Mjøen, Dag Olav Dahle, Karsten Midtvedt, Ivar Anders Eide, Anders Hartmann, Hallvard Holdaas
Publikováno v:
PLoS ONE, Vol 15, Iss 12, p e0243759 (2020)
Following a successful renal transplantation circulating markers of inflammation may remain elevated, and systemic inflammation is associated with worse clinical outcome in renal transplant recipients (RTRs). Vitamin D-receptor (VDR) activation is po
Externí odkaz:
https://doaj.org/article/24b38624c4dd4244bfcf20d78ac85d78
Autor:
Amin Ussif, Hege Pihlstrøm, Andreas Pasch, Hallvard Holdaas, Anders Hartmann, Knut Smerud, Anders Åsberg
Publikováno v:
BMC Nephrology, Vol 19, Iss 1, Pp 1-5 (2018)
Abstract Background Cardiovascular complications are common in kidney transplant patients and calcification propensity of blood, measured as T50, is associated with cardiovascular outcomes. Paricalcitol supplementation affects calcium/phosphate homeo
Externí odkaz:
https://doaj.org/article/43de48f2aaa343cc8df37dff9cf54efb
Autor:
Sadollah Abedini, MD, PhD, Lasse Gøransson, MD, PhD, Elinor Cockburn, MSc, PhD, Suzanne Kilany, BSc, Hallvard Holdaas, MD, PhD
Publikováno v:
Transplantation Direct, Vol 4, Iss 2, p e338 (2018)
Background. This study investigated medication adherence in kidney transplant patients (KTPs) converted from immediate-release tacrolimus (IR-T) to prolonged-release tacrolimus (PR-T)-based immunosuppression in routine practice. Methods. Nonintervent
Externí odkaz:
https://doaj.org/article/86a781c852f24f459a2b752ccf828c78
Publikováno v:
Journal of Transplantation, Vol 2016 (2016)
Malignancy after solid organ transplantation remains a major cause of posttransplant mortality. The mammalian target of rapamycin (mTOR) inhibitor class of immunosuppressants exerts various antioncogenic effects, and the mTOR inhibitor everolimus is
Externí odkaz:
https://doaj.org/article/7405c7be7f2b4d16af5c9231bbe782a8
Autor:
Jonathan B. Singer, Hallvard Holdaas, Alan G. Jardine, Bengt Fellstrøm, Ingrid Os, Georgina Bermann, Joanne M. Meyer
Publikováno v:
Journal of Lipid Research, Vol 48, Iss 9, Pp 2072-2078 (2007)
The Assessment of Lescol in Renal Transplantation clinical trial demonstrated the efficacy of fluvastatin in reducing cardiovascular (CV) disease in renal transplant recipients. The study included a voluntary pharmacogenetic component, enrolling 1,40
Externí odkaz:
https://doaj.org/article/4064c57140424362b0fad539ed8b2815
Autor:
Obbo W. Bredewold, Joe Chan, My Svensson, Annette Bruchfeld, Johan W. de Fijter, Hans Furuland, Josep M. Grinyo, Anders Hartmann, Hallvard Holdaas, Olof Hellberg, Alan Jardine, Lars Mjörnstedt, Karin Skov, Knut T. Smerud, Inga Soveri, Søren S. Sørensen, Anton-Jan van Zonneveld, Bengt Fellström
Publikováno v:
Bredewold, O W, Chan, J, Svensson, M, Bruchfeld, A, de Fijter, J W, Furuland, H, Grinyo, J M, Hartmann, A, Holdaas, H, Hellberg, O, Jardine, A, Mjörnstedt, L, Skov, K, Smerud, K T, Soveri, I, Sørensen, S S, Zonneveld, A-J V & Fellström, B 2023, ' Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients : A Randomized Clinical Trial ', Kidney Medicine, vol. 5, no. 1, 100574 . https://doi.org/10.1016/j.xkme.2022.100574
Bredewold, O W, Chan, J, Svensson, M, Bruchfeld, A, Fijter, J W D, Furuland, H, Grinyo, J M, Hartmann, A, Holdaas, H, Hellberg, O, Jardine, A, Mjörnstedt, L, Skov, K, Smerud, K T, Soveri, I, Sörensen, S S, van Zonneveld, A J & Fellström, B 2023, ' Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial ', Kidney Medicine, vol. 5, no. 1, 100574 . https://doi.org/10.1016/j.xkme.2022.100574
Bredewold, O W, Chan, J, Svensson, M, Bruchfeld, A, de Fijter, J W, Furuland, H, Grinyo, J M, Hartmann, A, Holdaas, H, Hellberg, O, Jardine, A, Mjörnstedt, L, Skov, K, Smerud, K T, Soveri, I, Sørensen, S S, Zonneveld, A J V & Fellström, B 2023, ' Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients : A Randomized Clinical Trial ', Kidney Medicine, vol. 5, no. 1, 100574 . https://doi.org/10.1016/j.xkme.2022.100574
Bredewold, O W, Chan, J, Svensson, M, Bruchfeld, A, Fijter, J W D, Furuland, H, Grinyo, J M, Hartmann, A, Holdaas, H, Hellberg, O, Jardine, A, Mjörnstedt, L, Skov, K, Smerud, K T, Soveri, I, Sörensen, S S, van Zonneveld, A J & Fellström, B 2023, ' Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial ', Kidney Medicine, vol. 5, no. 1, 100574 . https://doi.org/10.1016/j.xkme.2022.100574
Bredewold, O W, Chan, J, Svensson, M, Bruchfeld, A, de Fijter, J W, Furuland, H, Grinyo, J M, Hartmann, A, Holdaas, H, Hellberg, O, Jardine, A, Mjörnstedt, L, Skov, K, Smerud, K T, Soveri, I, Sørensen, S S, Zonneveld, A J V & Fellström, B 2023, ' Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients : A Randomized Clinical Trial ', Kidney Medicine, vol. 5, no. 1, 100574 . https://doi.org/10.1016/j.xkme.2022.100574
RATIONALE & OBJECTIVE: In kidney transplant recipients (KTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors compared with calcineurin inhibitor (CNI)-based regimens. Our object
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b69b94a611d7a310d374c44136f21cf6
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-498007
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-498007
Autor:
Christina Reith, Colin Baigent, Lisa Blackwell, Jonathan Emberson, Enti Spata, Kelly Davies, Heather Halls, Lisa Holland, Kate Wilson, Jane Armitage, Charlie Harper, David Preiss, Alistair Roddick, Anthony Keech, John Simes, Rory Collins, Elizabeth Barnes, Jordan Fulcher, William G Herrington, Adrienne Kirby, Borislava Mihaylova, Rachel O'Connell, Pierre Amarenco, Philip Barter, D John Betteridge (deceased), Michael Blazing, Jackie Bosch, Louise Bowman, Eugene Braunwald, Christopher P Cannon, Michael Clearfield, Stuart Cobbe, Helen M Colhoun, Björn Dahlöf, Barry Davis, James de Lemos, John R Downs, Paul N Durrington, Bengt Fellström, Ian Ford, Maria Grazia Franzosi, John Fuller (deceased), Curt Furberg, Robert Glynn, David Gordon, Antonio Gotto Jr, Richard Grimm, Ajay Gupta, C Morton Hawkins, Graham A Hitman, Hallvard Holdaas (deceased), Alan Jardine, J Wouter Jukema, John JP Kastelein, Sharon Kean, John Kjekshus, Genell Knatterud (deceased), Robert H Knopp (deceased), Wolfgang Koenig, Michael Koren, Vera Krane, Martin Landray, John LaRosa, Roberto Latini, Eva Lonn, Donata Lucci, Jean MacFadyen, Peter Macfarlane, Stephen MacMahon, Aldo Maggioni, Roberto Marchioli, Ian Marschner, Lemuel Moyé, Sabina Murphy, Andrew Neil, Enrico B Nicolis, Chris Packard, Sarah Parish, Terje R Pedersen, Richard Peto, Marc Pfeffer, Neil Poulter, Sara Pressel, Jeffrey Probstfield, Mahboob Rahman, Paul M Ridker, Michele Robertson, Frank Sacks, Naveed Sattar, Roland Schmieder, Patrick W Serruys, Peter Sever, John Shaw (deceased), James Shepherd (deceased), Lara Simpson, Peter Sleight (deceased), Luigi Tavazzi, Gianni Tognoni, Andrew Tonkin, Stella Trompet, Christoph Wanner, Hans Wedel, Stephen Weis, K Michael Welch, Harvey White, John Wikstrand, Lars Wilhelmsen, Stephen Wiviott, Robin Young, Salim Yusuf, Faiez Zannad, Hiroyuki Arashi, Robert Byington, Robert Clarke, Marcus Flather, Uri Goldbourt, Shinya Goto, Jemma Hopewell, Kees Hovingh, Patricia Kearney, George Kitas, Connie Newman, Marc S Sabatine, Greg Schwartz, Liam Smeeth, Jonathan Tobert, John Varigos, Junichi Yamaguchi
Publikováno v:
The Lancet, 400(10355), 832-845. Elsevier Limited
Background: Statin therapy is effective for the prevention of atherosclerotic cardiovascular disease and is widely prescribed, but there are persisting concerns that statin therapy might frequently cause muscle pain or weakness. We aimed to address t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4616cab962081ebdd901d4a6e1652a20
https://pure.amc.nl/en/publications/effect-of-statin-therapy-on-muscle-symptoms(c31d56e2-803e-4f3b-881a-6f09bfa1f0f4).html
https://pure.amc.nl/en/publications/effect-of-statin-therapy-on-muscle-symptoms(c31d56e2-803e-4f3b-881a-6f09bfa1f0f4).html
Autor:
Obbo W. Bredewold, Joe Chan, My Svensson, Annette Bruchfeld, Johan W. Fijter, Hans Furuland, Josep M. Grinyo, Anders Hartmann, Hallvard Holdaas, Olof Hellberg, Alan Jardine, Lars Mjörnstedt, Karin Skov, Knut T. Smerud, Inga Soveri, Sören S. Sörensen, Anton-Jan Zonneveld, Bengt Fellstrom
In renal transplant recipients (RTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors compared with calcineurin inhibitor (CNI)-based regimens. The aim of this randomized, multi-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5eac222c1e58682c102b6e3108952dd8
https://doi.org/10.21203/rs.3.rs-1283060/v1
https://doi.org/10.21203/rs.3.rs-1283060/v1
Autor:
Marit Rønning, Vidar Hjellvik, Solveig Sakshaug, Hege Salvesen Blix, Karsten Midtvedt, Anna Varberg Reisæter, Hallvard Holdaas, Anders Åsberg
Publikováno v:
International Journal of Environmental Research and Public Health, Vol 19, Iss 1370, p 1370 (2022)
International Journal of Environmental Research and Public Health (IJERPH)
International Journal of Environmental Research and Public Health; Volume 19; Issue 3; Pages: 1370
International Journal of Environmental Research and Public Health (IJERPH)
International Journal of Environmental Research and Public Health; Volume 19; Issue 3; Pages: 1370
Kidney transplant recipients (KTRs) experience increased risk of cardiovascular disease. Guidelines recommend HMG-CoA reductase inhibitor (statin) therapy when tolerated. We aimed to study changes in the prescription of statins and patients’ adhere
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c22e2d51aa335043d983997e2c55130
https://www.mdpi.com/1660-4601/19/3/1370
https://www.mdpi.com/1660-4601/19/3/1370